# An integrative approach to studying sphingolipid metabolism reveals p53 as a master regulator of the pathway

**Authors:** Botheina Ghandour, Saif Amin, Nihal Medatwal, Allen H. Lee, Gui-Qin Yu, Andrew E. Resnick, Sam B. Chiappone, Christopher J. Clarke, Daniel Canals, Yusuf A. Hannun, Chiara Luberto

PMC · DOI: 10.1016/j.jlr.2026.100994 · 2026-02-03

## TL;DR

This study shows that the tumor suppressor p53 plays a central role in regulating sphingolipid metabolism, especially in response to DNA damage.

## Contribution

The study identifies p53 as a master regulator of sphingolipid metabolism through novel flux tracing and enzymatic assays.

## Key findings

- Low-dose doxorubicin activates p53-dependent synthesis of specific dihydroceramide species.
- p53 suppresses dihydroceramide desaturase activity at both low and high doxorubicin doses.
- p53 influences sphingomyelin synthesis by affecting the Cer transport protein CERT1.

## Abstract

Sphingolipids (SPLs) are bioactive lipids playing vital functions in cellular stress responses. The tumor suppressor p53 has been implicated in regulating a few specific SPL enzymes; however, a comprehensive understanding of p53’s overall impact on SPL metabolism is lacking. Here, we employed an integrative biochemical approach combining a novel flux tracing method (using d17dihydrosphingosine) with in situ enzymatic activity assays in the context of treatment with doxorubicin (Dox), a DNA-damaging agent causing well-established dose-dependent activation of p53. Furthermore, our previous studies established dose-specific modulation of SPLs by sublethal (low dose) versus lethal (high dose) Dox. Here, we exploited this model to focus on the role of p53, and found i) both low and high Dox enhanced the rate of synthesis of select dihydroceramide species, d17:0/16:0, d17:0/18:0, and d17:0/20:0, implicating activation of specific ceramide (Cer) synthases (1/4 and 5/6), with p53 dependence only at low Dox (LD); ii) novel p53-dependent suppression of dihydroceramide desaturase activity at both Dox doses; iii) both doses of Dox impaired the synthesis of d17hexosylceramide and d17sphingomyelin, with an unanticipated role for p53 only at LD; and iv) with respect to inhibition of d17sphingomyelin synthesis, an investigation into Cer transport to the Golgi identified the Cer transport protein (CERT1) as a novel target of Dox (reduction of protein and activity) and p53 (reduction of activity, particularly at LD). These observations underscore p53's prominent role as a master regulator of SPL metabolism, inducing major remodeling of cellular SPL metabolism with extensive and integrated effects on SPL synthesis.

## Linked entities

- **Genes:** TP53 (tumor protein p53) [NCBI Gene 7157], cer (crammer) [NCBI Gene 37229], CERT1 (ceramide transporter 1) [NCBI Gene 10087]
- **Proteins:** cer (crammer), CERT1 (ceramide transporter 1)
- **Chemicals:** doxorubicin (PubChem CID 31703)

## Full-text entities

- **Genes:** SGPL1 (sphingosine-1-phosphate lyase 1) [NCBI Gene 8879] {aka NPHS14, RENI, S1PL, SPL}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}
- **Diseases:** tumor (MESH:D009369)
- **Chemicals:** lipids (MESH:D008055), ceramide (MESH:D002518), Dox (MESH:D004317), d17:0 (-), SPLs (MESH:D013107), dihydroceramide (MESH:C109343)

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12961331/full.md

---
Source: https://tomesphere.com/paper/PMC12961331